Histone deacetylases (HDACs) are frequently deregulated in cancer, and several HDAC inhibitors (HDACi) have gained approval for treating peripheral T cell lymphomas. Here, HDAC9 is linked to peripheral T-cell lymphoma, not otherwise specified.